Call Us: 1.800.873.5297

By

Your Pharmacist may be Switching your Medication

If you took a prescription pill recently, odds are it was generic: almost 70 percent of all prescriptions dispensed nationwide were generics in 2007. This totaled $58 billion in sales. Health care insurers see generics as an easy way to cut costs. Pharmacists in most states can freely give patients whichever version of a drug is cheapest, without telling the prescribing doctor; in some states, pharmacies are required to make this switch. And few of us complain when it happens: People who wouldn’t dream of substituting Diet Pepsi for Diet Coke, simply because of the taste, eagerly swap vital medications, because the change can cut co-pays in half.

When you fill a prescription, you expect to get the medication your doctor ordered. But pharmacists can legally give different versions of a drug without your knowledge and the consequences can be dire.

This is of special concern to epilepsy patients because doctors and patients spend much time fine-tuning the precise cocktail of medications the keep the seizures at bay. However, a generic may not work exactly like its brand-name counterpart, throwing off the precision in medications. One patient suffered a seizure shortly after her pharmacists unknowingly switched her medication. The consequences could have been graver had she been driving her car instead of her bicycle. As it was, when she fell off the bike, she suffered a broken leg, and a hairline fracture in her left eye socket.

Pharmacists commonly practice “therapeutic substitution,” where the pharmacist legally switches a drug prescribed by the physician — but without telling the patient or the physician. Usually, pharmacists replace a brand-name drug with a generic formulation of the exact same medication. Therapeutic substitution is similar but with one crucial distinction: The new drug is in the same class as the old and treats the same condition, but it’s not precisely the same medication.

Many lawmakers and health-policy experts say the trend of prescribing generics has little downside. “Generic drugs have the same active ingredient that brand-name drugs do and are made in FDA-approved plants, just as brand-name drugs are,” says Aaron S. Kesselheim, M.D., an instructor in medicine at Harvard Medical School in Boston. In an analysis recently published in The Journal of the American Medical Association, Dr. Kesselheim reviewed data from 47 clinical studies and found no evidence that patients on brand-name cardiovascular drugs had clinical outcomes superior to those on generics.

While the dosage may be the same, the drug’s release formula can make a crucial difference. Release formulas, which control how quickly a drug dissolves in your bloodstream, are something drug companies carefully develop and patent. And these release-formula patents often remain in place after the patent on a drug’s active ingredient has expired. That means generic companies must sometimes engineer their own release mechanism, as happened in the case of Budeprion XL 300 mg pill. Budeprion XL likely has a different release formula than its brand named counterpart. After patients and physicans made complaints to the FDA, it concluded in a 2008 report that patients’ problems were more likely caused by normal relapses of depression than by differences in the drugs. But the report in question and the original approval of Budeprion XL’s 300 mg pill were based solely on data Teva, Budeprion XL’s manufacturer, had submitted for the 150 mg pill; the agency’s judgment was that the doses were proportional and would behave similarly in the body. “Neither the FDA nor Teva did the required bioequivalence studies for this pill,” counters Tod Cooperman, M.D., president of ConsumerLab.com.

Physicians’ groups, including the American Academy of Neurology in St. Paul, Minnesota; the American Heart Association in Dallas; and the Endocrine Society in Chevy Chase, Maryland — all of whose members prescribe drugs that require delicate dosing — have warned doctors to look out for reactions to generics. They’ve also called on the FDA to study the issue in more detail.

There are ways to keep therapeutic substitution from happening to you. If your physician believes her drug of choice should not be switched for another, ask her to write “medically necessary,” “may not substitute,” or “DAW” — for “dispense as written” — on the prescription. That obligates the pharmacist to check with you and your physician before making any switches.

For more information please see:

http://www.sciencedaily.com/releases/2001/08/010829083837.htm
http://www.msnbc.msn.com/id/30940044//
http://www.msnbc.msn.com/id/30627962/

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.